Open access
Oct 2026
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.
Quadruplet therapy, combining anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors and dexamethasone, is now the standard induction treatment for newly diagnosed multiple myeloma (NDMM). However, treatment response is heterogeneous and molecular predictors are needed to guide early therapeutic decisions....
F. Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit et al.
· Nature Medicine · 0 citations